Orforglipron 在 2 型糖尿病中的心血管安全性和治疗潜力:来自 ACHIEVE-4 3 期试验的发现

Cardiovascular Safety and Therapeutic Potential of Orforglipron Versus Insulin Glargine in Type 2 Diabetes with Elevated Cardiovascular Risk: Insights from the ACHIEVE-4 Phase 3 Trial

A comprehensive review of the ACHIEVE-4 trial confirms orforglipron's cardiovascular safety non-inferior to insulin glargine in type 2 diabetes patients at elevated cardiovascular risk, highlighting its oral administration and safety profile advantages.